Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier

References

• Gandhi H, Sharma AK, Mahant S, et al. Recent advancements in brain tumor targeting using magnetic nanoparticles. Ther Deliv. 2020;11(2):97–112.
   PubMed Web of Science ®Google Scholar
• Jafari B, Pourseif MM, Barar J, et al. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin Drug Deliv. 2019;16(6):583–605.
   PubMed Web of Science ®Google Scholar
• Sun C, Ding Y, Zhou L, et al. Noninvasive nanoparticle strategies for brain tumor targeting. Nanomed. 2017;13(8):2605–2621.
   PubMed Web of Science ®Google Scholar
• Wei X, Chen X, Ying M, et al. Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B. 2014;4(3):193–201.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Morshed RA, Auffinger B, et al. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev. 2014;66:42–57.
   PubMed Web of Science ®Google Scholar
• Hempel C, Johnsen KB, Kostrikov S, et al. Brain tumor vessels-a barrier for drug delivery. Cancer Metastasis Rev. 2020;39(3):959–968.
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Gilbertson RJ. Brain Tumors: challenges and Opportunities to Cure. J Clin Oncol. 2017;35(21):2343–2345.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Adamski V, Rasch F, et al. Establishment of a glioblastoma in vitro (in)complete resection dual co-culture model suitable for drug testing. Ann Anat. 2020;228:151440.
   PubMed Web of Science ®Google Scholar
• Bette S, Barz M, Wiestler B, et al. Prognostic Value of Tumor Volume in Glioblastoma Patients: size Also Matters for Patients with Incomplete Resection. Ann Surg Oncol. 2018;25(2):558–564.
   PubMed Web of Science ®Google Scholar
• Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. 2014;121(5):1115–1123.
   PubMed Web of Science ®Google Scholar
• Trifiletti DM, Alonso C, Grover S, et al. Prognostic Implications of Extent of Resection in Glioblastoma: analysis from a Large Database. World Neurosurg. 2017;103:330–340.
   PubMed Web of Science ®Google Scholar
• Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16(8):509–520.
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–185.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, et al. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1(3):223–236.
   PubMed Web of Science ®Google Scholar
• He Y, Yao Y, Tsirka SE, et al. Cell-culture models of the blood-brain barrier. Stroke. 2014;45(8):2514–2526.
   PubMed Web of Science ®Google Scholar
• Stock AD, Gelb S, Pasternak O, et al. The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev. 2017;16(6):612–619.
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6(8):650–661.
   PubMed Web of Science ®Google Scholar
• Yao H, Wang K, Wang Y, et al. Enhanced blood-brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system. Biomaterials. 2015;37:345–352.
   PubMed Web of Science ®Google Scholar
• Barar J, Rafi MA, Pourseif MM, et al. Blood-brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts. 2016;6(4):225–248.
   PubMed Web of Science ®Google Scholar
• Willis CL. Imaging in vivo astrocyte/endothelial cell interactions at the blood-brain barrier. Methods Mol Biol. 2012;814:515–529.
   PubMedGoogle Scholar
• Omidi Y, Barar J. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts. 2012;2(1):5–22.
   PubMedGoogle Scholar
• Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
   PubMed Web of Science ®Google Scholar
• Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003;61:39–78.
   PubMedGoogle Scholar
• Watanabe T, Dohgu S, Takata F, et al. Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. Biol Pharm Bull. 2013;36(3):492–495.
   PubMed Web of Science ®Google Scholar
• Idris F, Hanna Muharram S, Zaini Z, et al. Establishment of murine in vitro blood-brain barrier models using immortalized cell lines: co-cultures of brain endothelial cells, astrocytes, and neurons. bioRxiv. 2018;435990:1-35.
   Google Scholar
• Nam L, Coll C, Erthal LCS, et al. Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme. Materials (Basel. 2018;11:5.
   Web of Science ®Google Scholar
• Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10(11):3728–3736.
   PubMed Web of Science ®Google Scholar
• Buie LW, Valgus JM. Current Treatment Options for the Management of Glioblastoma Multiforme. J Hematol Oncol Pharm. 2012;2:2.
   Google Scholar
• Wu M, Fan Y, Lv S, et al. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv. 2016;23(8):2720–2725.
   PubMed Web of Science ®Google Scholar
• Deligne C, Hachani J, Duban-Deweer S, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020;17(1):37.
   PubMed Web of Science ®Google Scholar
• Jeffrey P, Summerfield S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis. 2010;37(1):33–37.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437–449.
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Zhao Z, Montagne A, et al. Blood-Brain Barrier: from Physiology to Disease and Back. Physiol Rev. 2019;99(1):21–78.
   PubMed Web of Science ®Google Scholar
• Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: key functions and signaling pathways. Nat Neurosci. 2016;19(6):771–783.
   PubMed Web of Science ®Google Scholar
• Hopkins AM, DeSimone E, Chwalek K, et al. 3D in vitro modeling of the central nervous system. Prog Neurobiol. 2015;125:1–25.
   PubMed Web of Science ®Google Scholar
• Gomez-Zepeda D, Taghi M, Scherrmann JM, et al. Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics. 2019;12:1.
   Web of Science ®Google Scholar
• Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005;30(1):57–70.
   PubMed Web of Science ®Google Scholar
• Morris ME, Rodriguez-Cruz V, Felmlee MASLC, et al. Species Differences at the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers. Aaps J. 2017;19(5):1317–1331.
   PubMed Web of Science ®Google Scholar
• Tachikawa M, Uchida Y, Ohtsuki S, et al. Recent Progress in Blood–Brain Barrier and Blood–CSF Barrier Transport Research: pharmaceutical Relevance for Drug Delivery to the Brain. In: Hammarlund-Udenaes, M, de Lange, ECM, Thorne, RG (Eds.), Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches. New York: Springer, 2014: 23–62.
   Google Scholar
• Miller DS. Regulation of ABC transporters at the blood-brain barrier. Clin Pharmacol Ther. 2015;97(4):395–403.
   PubMed Web of Science ®Google Scholar
• Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295–1312.
   PubMed Web of Science ®Google Scholar
• Grube M, Hagen P, Jedlitschky G. Neurosteroid Transport in the Brain: role of ABC and SLC Transporters. Front Pharmacol. 2018;9:354.
   PubMed Web of Science ®Google Scholar
• Verscheijden LFM, van Hattem AC, Pertijs J, et al. Developmental patterns in human blood-brain barrier and blood-cerebrospinal fluid barrier ABC drug transporter expression. Histochem Cell Biol. 2020;154(3):265–273.
   PubMed Web of Science ®Google Scholar
• Warren MS, Zerangue N, Woodford K, et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res. 2009;59(6):404–413.
   PubMed Web of Science ®Google Scholar
• Qosa H, Miller DS, Pasinelli P, et al. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res. 2015;1628(Pt B):298–316.
   PubMedGoogle Scholar
• Kopcho N, Chang G, Komives EA. Dynamics of ABC Transporter P-glycoprotein in Three Conformational States. Sci Rep. 2019;9(1):15092.
   PubMedGoogle Scholar
• van Assema DM, Lubberink M, Rizzu P, et al. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer’s disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res. 2012;2(1):57.
   PubMedGoogle Scholar
• Schinkel AHP. Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):179–194.
   PubMed Web of Science ®Google Scholar
• de Trizio I, Errede M, d'Amati A, et al. Expression of P-gp in Glioblastoma: what we can Learn from Brain Development. Curr Pharm Des. 2020;26(13):1428–1437.
   PubMed Web of Science ®Google Scholar
• Spiegl-Kreinecker S, Buchroithner J, Elbling L, et al. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol. 2002;57(1):27–36.
   PubMed Web of Science ®Google Scholar
• Bahr O, Rieger J, Duffner F, et al. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells. Brain Pathol. 2003;13(4):482–494.
   PubMed Web of Science ®Google Scholar
• Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42(4):623–631.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24(9):1733–1744.
   PubMed Web of Science ®Google Scholar
• Katakowski M, Chopp M. Exosomes as Tools to Suppress Primary Brain Tumor. Cell Mol Neurobiol. 2016;36(3):343–352.
   PubMed Web of Science ®Google Scholar
• Mirzaei R, Sarkar S, Dzikowski L, et al. Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Oncoimmunology. 2018;7(10):e1478647.
   PubMed Web of Science ®Google Scholar
• Wood MJ, O’Loughlin AJ, Samira L. Exosomes and the blood-brain barrier: implications for neurological diseases. Ther Deliv. 2011;2(9):1095–1099.
   PubMedGoogle Scholar
• Rafi MA, Omidi Y. A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination. Bioimpacts. 2015;5(3):117–122.
   PubMed Web of Science ®Google Scholar
• O’Loughlin AJ, Woffindale CA, Wood MJ. Exosomes and the emerging field of exosome-based gene therapy. Curr Gene Ther. 2012;12(4):262–274.
   PubMed Web of Science ®Google Scholar
• Grapp M, Wrede A, Schweizer M, et al. Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun. 2013;4:2123.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhuang X, Zhang S, et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev. 2013;65(3):342–347.
   PubMed Web of Science ®Google Scholar
• Kudarha RR, Sawant KK. Chondroitin sulfate conjugation facilitates tumor cell internalization of albumin nanoparticles for brain-targeted delivery of temozolomide via CD44 receptor-mediated targeting. Drug Deliv Transl Res. 2020,in press.
   PubMed Web of Science ®Google Scholar
• Gumbleton M, Hollins AJ, Omidi Y, et al. Targeting caveolae for vesicular drug transport. J Control Release. 2003;87(1–3):139–151.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv. 2012;9(6):671–686.
   PubMed Web of Science ®Google Scholar
• Gao X, Li C. Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier. Small. 2014;10(3):426–440.
   PubMed Web of Science ®Google Scholar
• Parodi A, Rudzinska M, Deviatkin AA, et al. Established and Emerging Strategies for Drug Delivery Across the Blood-Brain Barrier in Brain Cancer. Pharmaceutics. 2019;11:5.
   Web of Science ®Google Scholar
• Wu SK, Tsai CL, Huang Y, et al. Microbubbles-Mediated Drug Delivery to Brain Tumor. Pharmaceutics. 2020;13:1.
   Web of Science ®Google Scholar
• Krizbai IA, Gasparics A, Nagyoszi P, et al. Endothelial-mesenchymal transition of brain endothelial cells: possible role during metastatic extravasation. PLoS One. 2015;10(3):e0119655.
   PubMed Web of Science ®Google Scholar
• Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392(10145):432–446.
   PubMed Web of Science ®Google Scholar
• Surgeons AAoN. Brain Tumors. (Ed.^(Eds) (2019 Jul 15)
   Google Scholar
• Perkins A, Liu G. Primary Brain Tumors in Adults: diagnosis and Treatment. Am Fam Physician. 2016;93(3):211–217.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820.
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61(3):215–225. discussion 226–219.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.
   PubMed Web of Science ®Google Scholar
• Long DM. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg. 1970;32(2):127–144.
   PubMed Web of Science ®Google Scholar
• Luissint AC, Artus C, Glacial F, et al. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23.
   PubMedGoogle Scholar
• Lochhead JJ, Yang J, Ronaldson PT, et al. Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders. Front Physiol. 2020;11:914.
   PubMed Web of Science ®Google Scholar
• Hasko J, Fazakas C, Molnar K, et al. Response of the neurovascular unit to brain metastatic breast cancer cells. Acta Neuropathol Commun. 2019;7(1):133.
   PubMed Web of Science ®Google Scholar
• Wilhelm I, Fazakas C, Molnar K, et al. Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases. J Cereb Blood Flow Metab. 2018;38(4):563–587.
   PubMed Web of Science ®Google Scholar
• Lee J, Lund-Smith C, Borboa A, et al. Glioma-induced remodeling of the neurovascular unit. Brain Res. 2009;1288:125–134.
   PubMed Web of Science ®Google Scholar
• Runkle EA, Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013;337(1):41–48.
   PubMed Web of Science ®Google Scholar
• Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100(3):323–331.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Laterra J, Westphal M, et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999;17(5–6):517–530.
   PubMed Web of Science ®Google Scholar
• Presta I, Vismara M, Novellino F, et al. Innate Immunity Cells and the Neurovascular Unit. Int J Mol Sci. 2018;19:12.
   Web of Science ®Google Scholar
• Gao H, Jiang X. Progress on the diagnosis and evaluation of brain tumors. Cancer Imaging. 2013;13(4):466–481.
   PubMed Web of Science ®Google Scholar
• Kim WY, Lee HY. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. Febs J. 2009;276(17):4653–4664.
   PubMed Web of Science ®Google Scholar
• Hanif F, Muzaffar K, Perveen K, et al. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.
   PubMedGoogle Scholar
• Jain RK, Di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8(8):610–622.
   PubMed Web of Science ®Google Scholar
• Plate KH, Mennel HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol. 1995;47(2–3):89–94.
   PubMedGoogle Scholar
• Lamszus K. PK. M Westphal Invasion as Limitation to Anti-angiogenic Glioma Therapy Acta Neurochir. 2003;88:pp 169–177.
   Google Scholar
• Bullitt E, Reardon DA, Smith JK. A review of micro-and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage. 2007;37:S116–S119.
   PubMed Web of Science ®Google Scholar
• Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597–609.
   PubMed Web of Science ®Google Scholar
• Ellingson BM, Harris RJ, Woodworth DC, et al. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017;19(1):89–98.
   PubMed Web of Science ®Google Scholar
• Albittar AA, Alhalabi O, Glitza Oliva IC. Immunotherapy for Melanoma. Adv Exp Med Biol. 2020;1244:51–68.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Fakhari D, Franz DN. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA. Expert Opin Pharmacother. 2020;21(11):1329–1336.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017;377(20):1954–1963.
   PubMed Web of Science ®Google Scholar
• Bell EH, Pugh SL, McElroy JP, et al. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. JAMA Oncol. 2017;3(6):784–792.
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA, et al. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11(1):80–91.
   PubMed Web of Science ®Google Scholar
• Solero CL, Monfardini S, Brambilla C, et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials. 1979;2(1):43–48.
   PubMedGoogle Scholar
• Walker MD, Gehan EA. Clinical studies in malignant gliomas and their treatment with the nitrosoureas. Cancer Treat Rep. 1976;60(6):713–716.
   PubMedGoogle Scholar
• Lee CY. Strategies of temozolomide in future glioblastoma treatment. Onco Targets Ther. 2017;10:265–270.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel. 2014;6(3):1769–1792.
   PubMed Web of Science ®Google Scholar
• Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–926.
   PubMed Web of Science ®Google Scholar
• Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, et al. Advances in Brain Tumor Surgery for Glioblastoma in Adults. Brain Sci. 2017;7:12.
   Web of Science ®Google Scholar
• Wilson TA, Karajannis MA, Harter DH. Glioblastoma multiforme: state of the art and future therapeutics. Surg Neurol Int. 2014;5:64.
   PubMedGoogle Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Fernandes C, Costa A, Osorio L, et al. Fernandes C, Costa A, Osorio L, et al. Current Standards of Care in Glioblastoma Therapy. In: De Vleeschouwer S, editor. Glioblastoma. Brisbane (AU): Codon Publications; 2017. p. 197-241.Current Standards of Care in Glioblastoma Therapy. In: De Vleeschouwer S, editor. Brisbane (AU): Codon Publications, 2017. p. 197-241.
   Google Scholar
• Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17(5):1516–1525.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar
• Medicine USNLo. ClinicalTrials.gov.
   Google Scholar
• Gainer JL, Sheehan JP, Larner JM, et al. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. J Neurosurg. 2017;126(2):460–466.
   PubMed Web of Science ®Google Scholar
• Norden AD, Schiff D, Ahluwalia MS, et al. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015;121(2):297–302.
   PubMed Web of Science ®Google Scholar
• Mulvihill JJ, Cunnane EM, Ross AM, et al. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. Nanomed. 2020;15(2):205–214.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J Control Release. 2007;122(3):345–348.
   PubMed Web of Science ®Google Scholar
• Grabrucker AM, Chhabra R, Belletti D, et al. Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems. In: Fricker G, Ott M, Mahringer Aeditors. The Blood Brain Barrier (BBB). Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 71–89.
   Google Scholar
• Wang L, Lieberman BP, Ploessl K, et al. Synthesis and evaluation of (1)(8)F labeled FET prodrugs for tumor imaging. Nucl Med Biol. 2014;41(1):58–67.
   PubMed Web of Science ®Google Scholar
• Cai L, Kirchleitner SV, Zhao D, et al. Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells. Int J Mol Sci. 2020;21:2.
   Web of Science ®Google Scholar
• Oddone N, Pederzoli F, Duskey JT, et al. ROS-responsive “smart” polymeric conjugate: synthesis. Characterization and Proof-of-concept Study Int J Pharm. 2019;570:118655.
   Google Scholar
• Zybina A, Anshakova A, Malinovskaya J, et al. Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy. Int J Pharm. 2018;547(1–2):10–23.
   PubMedGoogle Scholar
• Klukovits A, Krajcsi P. Mechanisms and therapeutic potential of inhibiting drug efflux transporters. Expert Opin Drug Metab Toxicol. 2015;11(6):907–920.
   PubMed Web of Science ®Google Scholar
• Newman MJ, Dixon R, Toyonaga B. OC144-093, a novel P glycoprotein inhibitor for the enhancement of anti-epileptic therapy. Novartis Found Symp. 2002;243: 213–226. discussion 226–230, 231–215.
   PubMedGoogle Scholar
• Sadanand V, Kankesan J, Yusuf A, et al. Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro. Cancer Lett. 2003;198(1):21–27.
   PubMed Web of Science ®Google Scholar
• Jekerle V, Klinkhammer W, Scollard DA, et al. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int J Cancer. 2006;119(2):414–422.
   PubMed Web of Science ®Google Scholar
• Zeng W, Kwan Law BY, Wai Wong VK, et al. HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model. Cancer Biol Med. 2020;17(4):986–1001.
   PubMed Web of Science ®Google Scholar
• Olson DP, Scadden DT, D’Aquila RT, et al. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1. AIDS. 2002;16(13):1743–1747.
   PubMed Web of Science ®Google Scholar
• Kannan P, Telu S, Shukla S, et al. The “specific” P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci. 2011;2(2):82–89.
   PubMed Web of Science ®Google Scholar
• Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28(6):655–660.
   PubMed Web of Science ®Google Scholar
• Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004;67(2):269–276.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, et al. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos. 2009;37(2):386–390.
   PubMed Web of Science ®Google Scholar
• Lu CT, Zhao YZ, Wong HL, et al. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine. 2014;9:2241–2257.
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88.
   PubMed Web of Science ®Google Scholar
• Vukelja SJ, Anthony SP, Arseneau JC, et al. Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs. 2007;18(3):283–289.
   PubMed Web of Science ®Google Scholar
• Sheleg SV, Korotkevich EA, Zhavrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol. 2002;60(1):53–59.
   PubMed Web of Science ®Google Scholar
• DiMeco F, Li KW, Tyler BM, et al. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg. 2002;97(5):1173–1178.
   PubMed Web of Science ®Google Scholar
• Current DX. Strategies for Brain Drug Delivery. Theranostics. 2018;8(6):1481–1493.
   PubMed Web of Science ®Google Scholar
• Sheikov N, McDannold N, Sharma S, et al. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol. 2008;34(7):1093–1104.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu H, Du X, et al. Increasing of blood-brain tumor barrier permeability through transcellular and paracellular pathways by microbubble-enhanced diagnostic ultrasound in a C6 glioma model. Front Neurosci. 2017;11:86.
   PubMed Web of Science ®Google Scholar
• Park J, Aryal M, Vykhodtseva N, et al. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption. J Control Release. 2017;250:77–85.
   PubMed Web of Science ®Google Scholar
• Samiotaki G, Karakatsani ME, Buch A, et al. Pharmacokinetic analysis and drug delivery efficiency of the focused ultrasound-induced blood-brain barrier opening in non-human primates. Magn Reson Imaging. 2017;37:273–281.
   PubMed Web of Science ®Google Scholar
• Xhima K, Weber-Adrian D, Silburt J. Glutamate induces blood–brain barrier permeability through activation of N-methyl-D-aspartate receptors. J Neurosci. 2016;36(49):12296–12298.
   PubMed Web of Science ®Google Scholar
• Smart Multifunctional OY. Theranostics: simultaneous Diagnosis and Therapy of Cancer. BioImpacts. 2011;1(3):145–147.
   PubMedGoogle Scholar
• Wu X, Yang H, Yang W, et al. Nanoparticle-based diagnostic and therapeutic systems for brain tumors. J Mater Chem B. 2019;7(31):4734–4750.
   PubMed Web of Science ®Google Scholar
• Barar J, Omidi Y. Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts. 2014;4(1):3–14.
   PubMedGoogle Scholar
• Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. J Nucl Med. 2014;55(12):1919–1922.
   PubMed Web of Science ®Google Scholar
• Eslaminejad T, Nematollahi-Mahani SN, Ansari M. Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles. Curr Gene Ther. 2017;17(1):59–69.
   PubMed Web of Science ®Google Scholar
• Wahab R, Kaushik N, Khan F, et al. Gold quantum dots impair the tumorigenic potential of glioma stem-like cells via beta-catenin downregulation in vitro. Int J Nanomedicine. 2019;14:1131–1148.
   PubMed Web of Science ®Google Scholar
• Hettiarachchi SD, Graham RM, Mintz KJ, et al. Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors. Nanoscale. 2019;11(13):6192–6205.
   PubMed Web of Science ®Google Scholar
• Shamsipour M, Mansouri AM, Moradipour P. Temozolomide Conjugated Carbon Quantum Dots Embedded in Core/Shell Nanofibers Prepared by Coaxial Electrospinning as an Implantable Delivery System for Cell Imaging and Sustained Drug Release. AAPS PharmSciTech. 2019;20(7):259.
   PubMed Web of Science ®Google Scholar
• Razpotnik R, Novak N, Curin Serbec V, et al. Targeting Malignant Brain Tumors with Antibodies. Front Immunol. 2017;8:1181.
   PubMed Web of Science ®Google Scholar
• Alizadeh S, Esmaeili A, Barzegari A, et al. Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours. J Drug Target. 2020;28(7–8):700–713.
   PubMed Web of Science ®Google Scholar
• Tamura K, Wakimoto H, Agarwal AS, et al. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013;21(1):68–77.
   PubMed Web of Science ®Google Scholar
• Duebgen M, Martinez-Quintanilla J, Tamura K, et al. Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. J Natl Cancer Inst. 2014;106(6):dju090.
   PubMedGoogle Scholar
• Martinez-Quintanilla J, He D, Wakimoto H, et al. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther. 2015;23(1):108–118.
   PubMed Web of Science ®Google Scholar
• Pisklakova A, McKenzie B, Zemp F, et al. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro Oncol. 2016;18(8):1088–1098.
   PubMed Web of Science ®Google Scholar
• Spinelli C, Adnani L, Choi D, et al. Extracellular Vesicles as Conduits of Non-Coding RNA Emission and Intercellular Transfer in Brain Tumors. Noncoding RNA. 2018;5:1.
   Web of Science ®Google Scholar
• Van’t Root M, Lowik C, Mezzanotte L. Targeting Nanomedicine to Brain Tumors: latest Progress and Achievements. Curr Pharm Des. 2017;23(13):1953–1962.
   PubMed Web of Science ®Google Scholar
• Yang T, Martin P, Fogarty B, et al. Exosome delivered anticancer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio. Pharm Res. 2015;32(6):2003–2014.
   PubMed Web of Science ®Google Scholar
• Monaco I, Camorani S, Colecchia D, et al. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. J Med Chem. 2017;60(10):4510–4516.
   PubMed Web of Science ®Google Scholar
• Han L, Kong DK, Zheng MQ, et al. Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging. ACS Nano. 2016;10(4):4209–4218.
   PubMed Web of Science ®Google Scholar
• Li S, Amat D, Peng Z, et al. Transferrin conjugated nontoxic carbon dots for doxorubicin delivery to target pediatric brain tumor cells. Nanoscale. 2016;8(37):16662–16669.
   PubMed Web of Science ®Google Scholar
• Tang J, Huang N, Zhang X, et al. Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma. Int J Nanomedicine. 2017;12:3899–3911.
   PubMed Web of Science ®Google Scholar
• Orringer DA, Koo YE, Chen T, et al. In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation. Neurosurgery. 2009;64(5):965–971. discussion 971–962.
   PubMed Web of Science ®Google Scholar
• Brioschi A, Zenga F, Zara GP, et al. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res. 2007;29(3):324–330.
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, et al. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomed. 2016;11(6):673–692.
   PubMed Web of Science ®Google Scholar
• Kang JH, Cho J, Ko YT. Investigation on the effect of nanoparticle size on the blood-brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice. J Drug Target. 2019;27(1):103–110.
   PubMed Web of Science ®Google Scholar
• Betzer O, Shilo M, Opochinsky R, et al. The effect of nanoparticle size on the ability to cross the blood-brain barrier: an in vivo study. Nanomed. 2017;12(13):1533–1546.
   PubMed Web of Science ®Google Scholar
• De Jong WH, Hagens WI, Krystek P, et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials. 2008;29(12):1912–1919.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Leroux JC. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161(2):152–163.
   PubMed Web of Science ®Google Scholar
• Bors LA, Erdő F. Overcoming the blood–brain barrier. challenges and tricks for CNS drug delivery. Sci Pharm. 2019;87(1):6.
   Web of Science ®Google Scholar
• Vecsernyés M, Fenyvesi F, Bácskay I, et al. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. Arch Med Res. 2014;45(8):711–729.
   PubMed Web of Science ®Google Scholar
• Tilloy S, Monnaert V, Fenart L, et al. Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg Med Chem Lett. 2006;16(8):2154–2157.
   PubMed Web of Science ®Google Scholar
• Gaillard, PJ, Visser CC, de Boer M, et al. Blood-to-Brain Drug Delivery Using Nanocarriers. In: Hammarlund-Udenaes, M, de Lange, ECM, Thorne, RG (Eds.), Drug Delivery to the Brain: Physiological Concepts, Methodologies and Approaches. New York: Springer, 2014: 23–62.
   Google Scholar
• Rip J. Liposome technologies and drug delivery to the CNS. Drug Discov Today Technol. 2016;20:53–58.
   PubMedGoogle Scholar
• Noble GT, Stefanick JF, Ashley JD, et al. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32(1):32–45.
   PubMed Web of Science ®Google Scholar
• Gao H. Perspectives on Dual Targeting Delivery Systems for Brain Tumors. J Neuroimmune Pharmacol. 2017;12(1):6–16.
   PubMed Web of Science ®Google Scholar
• Gao JQ, Lv Q, Li LM, et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials. 2013;34(22):5628–5639.
   PubMed Web of Science ®Google Scholar
• Kang S, Duan W, Zhang S, et al. Muscone/ RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics. 2020;10(10):4308–4322.
   PubMed Web of Science ®Google Scholar
• Kuo YC, Lee CH. Dual targeting of solid lipid nanoparticles grafted with 83-14 MAb and anti-EGF receptor for malignant brain tumor therapy. Life Sci. 2016;146:222–231.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiao X, Zhu J, et al. Lactoferrin- and RGD-comodified. Temozolomide and Vincristine-coloaded Nanostructured Lipid Carriers for Gliomatosis Cerebri Combination Therapy Int J Nanomedicine. 2018;13:3039–3051.
   Google Scholar
• Xu M, Li G, Zhang H, et al. Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect. Drug Deliv. 2020;27(1):983–995.
   PubMed Web of Science ®Google Scholar
• Marin E, Briceno MI, Caballero-George C. Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine. 2013;8:3071–3090.
   PubMed Web of Science ®Google Scholar
• Bernal GM, LaRiviere MJ, Mansour N, et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomed. 2014;10(1):149–157.
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target. 2009;17(8):564–574.
   PubMed Web of Science ®Google Scholar
• de la Torre C, The Delivery CV. Challenge in Neurodegenerative Disorders: the Nanoparticles Role in Alzheimer’s Disease Therapeutics and Diagnostics. Pharmaceutics. 2018;10:4.
   Web of Science ®Google Scholar
• Uram L, Misiorek M, Pichla M, et al. The Effect of Biotinylated PAMAM G3 Dendrimers Conjugated with COX-2 Inhibitor (celecoxib) and PPARgamma Agonist (Fmoc-L-Leucine) on Human Normal Fibroblasts. Immortalized Keratinocytes and Glioma Cells in Vitro Mol. 2019;24:20.
   Google Scholar
• Velasco-Aguirre C, Morales F, Gallardo-Toledo E, et al. Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches. Int J Nanomedicine. 2015;10:4919–4936.
   PubMed Web of Science ®Google Scholar
• Sela H, Cohen H, Elia P, et al. Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB. J Nanobiotechnology. 2015;13:71.
   PubMed Web of Science ®Google Scholar
• Cole LE, Ross RD, Tilley JM, et al. Gold nanoparticles as contrast agents in x-ray imaging and computed tomography. Nanomed. 2015;10(2):321–341.
   PubMed Web of Science ®Google Scholar
• Feng Q, Shen Y, Fu Y, et al. Self-Assembly of Gold Nanoparticles Shows Microenvironment-Mediated Dynamic Switching and Enhanced Brain Tumor Targeting. Theranostics. 2017;7(7):1875–1889.
   PubMed Web of Science ®Google Scholar
• CNT OY. Nanobombs for Specific Eradication of Cancer Cells: A New Concept in Cancer Theranostics. Bioimpacts. 2011;1(4):199–201.
   PubMedGoogle Scholar
• Dolatkhah M, Hashemzadeh N, Barar J, et al. Graphene-based multifunctional nanosystems for simultaneous detection and treatment of breast cancer. Colloids Surf B Biointerfaces. 2020;193:111104.
   PubMed Web of Science ®Google Scholar
• Vardharajula S, Ali SZ, Tiwari PM, et al. Functionalized carbon nanotubes: biomedical applications. Int J Nanomedicine. 2012;7:5361.
   PubMed Web of Science ®Google Scholar
• Kafa H, Wang JT, Rubio N, et al. The interaction of carbon nanotubes with an in vitro blood-brain barrier model and mouse brain in vivo. Biomaterials. 2015;53:437–452.
   PubMed Web of Science ®Google Scholar
• Gao X, Yue Q, Liu Y, et al. Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins. Theranostics. 2018;8(11):3126–3137.
   PubMed Web of Science ®Google Scholar
• Sattiraju A, Sun Y, Solingapuram Sai KK, et al. Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part IV: Image-Guided, Remote-Controlled Opening of the Blood-Brain Barrier for Systemic Brain Tumor Therapy. In: De Vleeschouwer S, editor Glioblastoma. Brisbane (AU): Exon Publications, 2017:395-404.
   Google Scholar
• Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci. 2001;90(11):1681–1698.
   PubMed Web of Science ®Google Scholar
• Li Y, Li D, Zhao P, et al. Systems in Diagnosis of Alzheimer’s Disease and Biomimetic Modeling. Micromachines (Basel. 2020;11:9.
   Web of Science ®Google Scholar
• Wang X, Hou Y, Ai X, et al. Potential applications of microfluidics based blood brain barrier (BBB)-on-chips for in vitro drug development. Biomed Pharmacother. 2020;132:110822.
   PubMed Web of Science ®Google Scholar
• Prabhakarpandian B, Shen MC, Nichols JB, et al. SyM-BBB: a microfluidic Blood Brain Barrier model. Lab Chip. 2013;13(6):1093–1101.
   PubMed Web of Science ®Google Scholar
• Di Marco A, Vignone D, Gonzalez Paz O, et al. Establishment of an in Vitro Human Blood-Brain Barrier Model Derived from Induced Pluripotent Stem Cells and Comparison to a Porcine Cell-Based System. Cells. 2020; 9(4):1-22.
   Web of Science ®Google Scholar
• Smith M, Omidi Y, Gumbleton M. Primary porcine brain microvascular endothelial cells: biochemical and functional characterisation as a model for drug transport and targeting. J Drug Target. 2007;15(4):253–268.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Barar J, Ahmadian S, et al. Characterization and astrocytic modulation of system L transporters in brain microvasculature endothelial cells. Cell Biochem Funct. 2008;26(3):381–391.
   PubMed Web of Science ®Google Scholar
• Barar J, Gumbleton M, Asadi M, et al. Barrier functionality and transport machineries of human ECV304 cells. Med Sci Monit. 2010;16(1):BR52–60.
   PubMed Web of Science ®Google Scholar
• Nakhlband A, Omidi Y. Barrier functionality of porcine and bovine brain capillary endothelial cells. Bioimpacts. 2011;1(3):153–159.
   PubMedGoogle Scholar
• Omidi Y, Campbell L, Barar J, et al. Evaluation of the immortalised mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res. 2003;990(1–2):95–112.
   PubMed Web of Science ®Google Scholar
• Franke H, Galla H, Beuckmann CT. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Brain Res Protoc. 2000;5(3):248–256.
   PubMedGoogle Scholar
• Motallebnejad P, Thomas A, Swisher SL, et al. An isogenic hiPSC-derived BBB-on-a-chip. Biomicrofluidics. 2019;13(6):064119.
   PubMed Web of Science ®Google Scholar
• Helms HC, Abbott NJ, Burek M, et al. In vitro models of the blood-brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862–890.
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Mathew RK, Rutka JT. Diffuse Intrinsic Pontine Glioma: clinical Features, Molecular Genetics, and Novel Targeted Therapeutics. J Korean Neurosurg Soc. 2018;61(3):343–351.
   PubMed Web of Science ®Google Scholar
• Hammarlund-Udenaes M, Friden M, Syvanen S, et al. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–1750.
   PubMed Web of Science ®Google Scholar
• Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther. 1996;277(3):1550–1559.
   PubMed Web of Science ®Google Scholar
• Smith QR, Samala R. In Situ and In Vivo Animal Models. In: Hammarlund-Udenaes, M, de Lange, ECM, Thorne, RG (Eds.), In: Drug Delivery to the Brain: physiological Concepts, Methodologies and Approaches. New York: Springer, 2014: 199–212.
   Google Scholar
• Raimondi I, Izzo L, Tunesi M, et al. Organ-On-A-Chip in vitro Models of the Brain and the Blood-Brain Barrier and Their Value to Study the Microbiota-Gut-Brain Axis in Neurodegeneration. Front Bioeng Biotechnol. 2019;7(435):1-17.
   PubMedGoogle Scholar
• Mofazzal Jahromi MA, Abdoli A, Rahmanian M, et al. Microfluidic Brain-on-a-Chip: perspectives for Mimicking Neural System Disorders. Mol Neurobiol. 2019;56(12):8489–8512.
   PubMed Web of Science ®Google Scholar
• Miccoli B, Braeken D, Li YE. Brain-on-a-chip Devices for Drug Screening and Disease Modeling Applications. Curr Pharm Des. 2018;24(45):5419–5436.
   PubMed Web of Science ®Google Scholar